Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM ImmunoTech ( (AIM) ) has issued an announcement.
On July 31, 2025, AIM ImmunoTech Inc. announced the closing of its public offering, raising approximately $8.0 million through the sale of 2,000,000 shares of common stock and accompanying warrants. The offering, managed by Maxim Group LLC, is expected to bolster the company’s financial position, potentially enhancing its ability to advance its therapeutic developments.
The most recent analyst rating on (AIM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall score is primarily impacted by its challenging financial performance and bearish technical indicators. Despite a promising development in clinical trials, ongoing financial distress and regulatory challenges weigh heavily on the stock’s outlook.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is Ampligen®, an investigational drug with broad spectrum activity in clinical trials for significant global health issues.
Average Trading Volume: 130,847
Technical Sentiment Signal: Sell
Current Market Cap: $2.41M
See more insights into AIM stock on TipRanks’ Stock Analysis page.